实时尿替诺福韦检测改善HIV既往病毒学失败者的用药依从性:一项随机对照试验
BACKGROUND: Scalable strategies to detect and address inadequate adherence to antiretroviral therapy (ART) are a high priority towards meeting UNAIDS 95-95-95 targets.…
核心结论
- UTRA强化依从支持未显著提高病毒学抑制率,但与干血斑TFV-DP浓度升高相关,后者与较低CRP水平相关。
临床怎么用
- UTRA可用于实时评估替诺福韦类药物的近期依从性,辅助识别依从性不佳者。
- 对于既往病毒学失败者,UTRA强化支持可能改善长期药物暴露并减轻炎症,但未显著提高病毒学抑制率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Scalable strategies to detect and address inadequate adherence to antiretroviral therapy (ART) are a high priority towards meeting UNAIDS 95-95-95 targets. A urine tenofovir rapid assay (UTRA) at the point-of-care improves adherence among pre-exposure prophylaxis recipients and virologic suppression (VS) in a pre-post study of people with HIV (PWH). Here, we conducted the first randomized trial of UTRA-enhanced adherence support vs standard of care among PWH. METHODS: Participants receiving dolutegravir (DTG)- or protease inhibitor (PI)-based ART were randomized to UTRA-enhanced adherence support (n = 100) vs standard of care (n = 100). The primary outcome was VS, HIV-1 RNA <50 copies/mL, at 12-months and secondary outcome was VS at 6 months. To explore ART adherence over the preceding 6-8 weeks, tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) was quantified. C-reactive protein (CRP) was measured as an inflammatory marker. RESULTS: At the 12-month visit, 59/80 (74%) in the intervention and 48/75 (64%) in the control arm achieved VS (the same proportion as at 6 months; P = .2); TFV-DP concentrations (median, IQR) in DBS were significantly higher in the intervention arm: 884 (491-1296) vs 598 (239-964) fmol/3-mm DBS punch in the control arm (P < .01). Higher TFV-DP DBS concentrations correlated with a slight decrease in CRP (Spearman's rho = -0.19; P = .02). CONCLUSIONS: UTRA-enhanced adherence support did not result in a significantly higher VS rate but was associated with increased TFV-DP in DBS-in turn, associated with lower CRP levels-suggesting that UTRA-enhanced adherence support improves long-term drug exposure and could also reduce HIV-associated inflammation. CLINICAL TRIALS REGISTRATION: clinicaltrials.gov (https://clinicaltrials.gov/study/NCT05333679).
引用
- van Zyl GU, Decloedt E, Jennings L, et al. A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial. Clin Infect Dis. 2025. PMID: 40578842. doi:10.1093/cid/ciaf337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。